Quotient Bioresearch was a UK-based contract research organization holding company.

Quotient’s various divisions provided early-stage and specialist drug development services to the global life science industry. In December 2013, Bridgepoint Development Capital acquired Quotient’s Clinical Division and in February 2016, Pharmaron acquired most of the company’s remaining assets.